Published in Ann Intern Med on March 01, 1995
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol (2010) 3.19
Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst (2006) 3.18
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005. J Clin Oncol (2009) 2.52
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A (1996) 2.34
Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut (2002) 2.31
Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res (2010) 2.18
Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer (2001) 2.12
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut (2005) 1.87
Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut (2002) 1.81
Tumour markers of prognosis in colorectal cancer. Br J Cancer (1999) 1.68
Factors that influence 12 or more harvested lymph nodes in early-stage colorectal cancer. World J Surg (2009) 1.54
Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients. World J Surg Oncol (2007) 1.37
Adjuvant treatment for colorectal cancer. BMJ (1996) 1.36
Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist (2006) 1.35
Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut (2011) 1.32
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol (2010) 1.27
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. Dtsch Arztebl Int (2009) 1.25
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol (2008) 1.24
Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer (2008) 1.19
Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol (2010) 1.17
Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res (2010) 1.14
DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. Cancer Biol Ther (2011) 1.11
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer (2003) 1.10
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis (2003) 1.07
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int J Colorectal Dis (2006) 1.06
Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer (1998) 1.06
Ex vivo sentinel node mapping in carcinoma of the colon and rectum. Ann Surg (2001) 1.05
Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br J Cancer (2001) 1.04
Clinical trials: discerning hype from substance. Ann Intern Med (2010) 1.02
Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark (2006) 1.01
Gene expression profiles in stages II and III colon cancers: application of a 128-gene signature. Int J Colorectal Dis (2012) 1.01
Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol (2010) 1.01
Death from early colorectal cancer is predicted by the presence of transcripts of the REG gene family. Br J Cancer (2000) 0.98
The Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colorectal Cancer is Independent of Age and Comorbidity. J Geriatr Oncol (2010) 0.97
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer (2007) 0.96
Current status of adjuvant therapy for colon cancer. Gastrointest Cancer Res (2007) 0.95
Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer (2000) 0.93
Management of hepatic metastases from colorectal cancer. Clin Colon Rectal Surg (2005) 0.93
Chemoradiotherapy for colorectal cancer. Gut (2005) 0.93
Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients. Int J Colorectal Dis (2008) 0.93
Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor. Therap Adv Gastroenterol (2008) 0.92
Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy. Gastrointest Cancer Res (2009) 0.91
Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Support Care Cancer (2004) 0.90
Effect of preoperative hyperfibrinogenemia on recurrence of colorectal cancer without a systemic inflammatory response. World J Surg (2009) 0.90
Comparison of prognostic genomic predictors in colorectal cancer. PLoS One (2013) 0.90
Systematic heterogeneity and prognostic significance of cell proliferation in colorectal cancer. Br J Cancer (1998) 0.90
Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival. J Clin Pathol (2004) 0.90
The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. Trials (2011) 0.89
Biomarker selection for detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR. Br J Cancer (2006) 0.88
Ultra staging to unmask the prescribing of adjuvant therapy in cancer patients: the future opportunity to image micrometastases using total-body 18F-FDG PET scanning. J Nucl Med (2014) 0.88
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol (2014) 0.88
Productivity savings from colorectal cancer prevention and control strategies. Am J Prev Med (2011) 0.88
Levamisole induced apoptosis in cultured vascular endothelial cells. Br J Pharmacol (2000) 0.88
Development and progression of colorectal neoplasia. Cancer Biomark (2010) 0.85
Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner. Cancer Biol Ther (2010) 0.85
Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. BMC Gastroenterol (2012) 0.85
Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer. Gut (2006) 0.84
Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort. Br J Cancer (2014) 0.83
Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer (2006) 0.83
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study. Br J Cancer (1998) 0.83
Evolution in the treatment of metastatic colorectal carcinoma of the liver. World J Gastroenterol (2006) 0.83
The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs (2000) 0.82
Comparison of ex vivo and in vivo injection of blue dye in sentinel lymph node mapping for colorectal cancer. World J Surg (2009) 0.81
Hyaluronan-cisplatin conjugate nanoparticles embedded in Eudragit S100-coated pectin/alginate microbeads for colon drug delivery. Int J Nanomedicine (2013) 0.81
Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer. J Gastrointest Cancer (2013) 0.81
Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks. BMC Cancer (2007) 0.81
Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. Support Care Cancer (2004) 0.81
The Feasibility of an Ex-vivo Sentinel Lymph Mapping Using Preoperative Radioisotope Injection in Cases of Extraperitoneal Rectal Cancer. J Korean Soc Coloproctol (2011) 0.81
The lymph node ratio optimises staging in patients with node positive colon cancer with implications for adjuvant chemotherapy. Int J Colorectal Dis (2014) 0.80
The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort. J Transl Med (2014) 0.80
cDNA array analysis for prediction of hepatic metastasis of colorectal carcinoma. Surg Today (2006) 0.80
Optimal use of adjuvant chemotherapy in stage II colorectal cancer. Int J Colorectal Dis (2011) 0.79
Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy. Int J Colorectal Dis (2007) 0.79
The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer. Br J Cancer (1998) 0.79
Effects of Triterpenoid Glycosides from Fresh Ginseng Berry on SW480 Human Colorectal Cancer Cell Line. Cancer Res Treat (2011) 0.79
Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity. Mutat Res (2013) 0.79
Influence of socioeconomic status and hospital type on disparities of lymph node evaluation in colon cancer patients. Cancer (2011) 0.79
Expression of MSP58 in human colorectal cancer and its correlation with prognosis. Med Oncol (2012) 0.78
Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility? Clin Chem (2016) 0.78
Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer. Int J Colorectal Dis (2011) 0.78
Chemotherapy for Stage II Colon Cancer. Clin Colon Rectal Surg (2015) 0.78
Prognostic factors assessed for 15,096 patients with colon cancer in stages I and II. World J Surg (2012) 0.78
The prognostic value of haplotypes in the vascular endothelial growth factor a gene in colorectal cancer. Cancers (Basel) (2010) 0.78
Visual AIDS for multimodal treatment options to support decision making of patients with colorectal cancer. BMC Med Inform Decis Mak (2012) 0.77
Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer (2016) 0.77
The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients. Cancer Med (2016) 0.77
Adjuvant therapy of colon cancer: current status and future developments. Clin Colon Rectal Surg (2005) 0.77
High Expression of DARPP-32 in Colorectal Cancer Is Associated With Liver Metastases and Predicts Survival for Dukes A and B Patients: Results of a Pilot Study. Int Surg (2015) 0.76
Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70. PLoS One (2015) 0.76
Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. PLoS One (2014) 0.76
Lymph node harvest in Dukes' A cancer pathologist may need to consider fat dissolving technique: an observational study. ScientificWorldJournal (2012) 0.76
Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status. Cancer Biol Ther (2016) 0.76
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci (2001) 42.21
A multiple testing procedure for clinical trials. Biometrics (1979) 26.80
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med (1990) 7.92
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med (1998) 7.60
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med (2001) 7.59
Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med (1991) 7.21
Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA (1992) 6.99
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med (1993) 6.77
One-sample multiple testing procedure for phase II clinical trials. Biometrics (1982) 6.45
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med (1980) 6.12
Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol (2003) 5.71
An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA (1993) 5.43
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol (2001) 5.31
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol (1996) 4.92
Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med (1997) 4.64
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med (2000) 4.50
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet (2000) 4.43
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol (1989) 4.03
Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA (1994) 4.01
Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA (1993) 3.91
Prognosis in primary biliary cirrhosis: model for decision making. Hepatology (1989) 3.83
Designs for group sequential tests. Control Clin Trials (1984) 3.56
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst (1998) 3.50
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol (1989) 3.44
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med (1985) 3.36
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med (1994) 3.29
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol (1997) 3.04
Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med (1998) 2.95
Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Stat Med (1998) 2.84
Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation (2000) 2.71
Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol (2001) 2.54
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol (1998) 2.51
Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. Biometrics (1989) 2.51
Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst (1999) 2.40
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med (1991) 2.37
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med (1997) 2.25
Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol (1999) 2.22
Temperature and Excitability. J Physiol (1896) 2.21
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA (1999) 2.21
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res (1998) 2.21
Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics (1995) 2.19
The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys (1994) 2.17
Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol (1982) 2.12
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. J Clin Oncol (1989) 2.02
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer (2001) 1.99
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol (2001) 1.94
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol (1991) 1.93
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol (1994) 1.93
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst (1990) 1.92
Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol (1991) 1.91
Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol (2001) 1.87
An effect of pactamycin on the initiation of protein synthesis in reticulocytes. Biochem Biophys Res Commun (1970) 1.79
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol (1990) 1.74
An assay for the mitogenic activity of phytohemagglutinin preparations. Blood (1965) 1.73
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer (1978) 1.71
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med (1989) 1.70
Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol (1994) 1.67
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol (2013) 1.62